Finance
S&P 500 7,757.17 +44.60 +0.58% Dow 52,856.09 +360.19 +0.69% Nasdaq 26,702.86 +278.04 +1.05% NYSE Composite 24,253.12 +62.52 +0.26% Russell 2000 2,781.02 +7.60 +0.27% VIX 16.68 -0.63 -3.64%

ACUT · Accustem Sciences Inc

OTC MARKETS - Real Time Price • USD

Accustem Sciences Inc (ACUT)

OTC MARKETS Biotechnology
Move probability → Options chain →
$0.15 +0.00 (+0.00%)
● Overnight
DAY'S RANGE $0.15
$0.15 $0.16
52-WEEK RANGE $0.15
$0.12 $1.58

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$2.4M
P/E (TTM1)—
EPS2 (TTM)$-0.10
Div Yield—
Beta31.88
Volume—
Open0.16
Prev Close0.15
Bid / Ask— / —
Next Earnings 2026-11-04

Analyst Recommendations

No analyst recommendation data available.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
ACUT -81.88%
vs S&P 500 -85.90%
1-YEAR RETURN
ACUT -23.85%
vs S&P 500 -33.43%
6-MONTH RETURN
ACUT -82.15%
3-MONTH RETURN
ACUT -53.94%

Valuation Measures & Ratios

Enterprise Value4$2.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book76.40
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-217.13%
Return on Assets (ROA9)-105.30%
Avg Volume (3M)4,710
Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short3,534
Change from Prior Settlement-8.23%
% of Float—
Days to Cover (Short Ratio)8.16

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Not investment advice — read several signals together.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

History limited by data provider; markers are heuristics, not signals.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

  • Latest SEC filing is Form 10-Q, filed 2026-08-14; review it for current changes and risks. SEC EDGAR ↗

Potential concerns

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

No accessible free API for these — links go to the source directly.

Morningstar MarketBeat

Financials

Income statement

Line item Jun '26Mar '26Sep '25Jun '25Mar '25Sep '24Jun '24Mar '24
Revenue $98.4K — — — — — — —
Operating income -$252.6K -$485.9K -$399.9K -$401.4K -$440.4K -$328.2K -$278.2K -$526.6K
Net income -$252.6K -$485.9K -$399.9K -$401.4K -$440.4K -$328.2K -$278.2K -$526.6K
EPS (diluted) $-0.02 $-0.03 $-0.02 $-0.02 $-0.03 $-0.03 $-0.02 $-0.05
EPS (basic) $-0.02 $-0.03 $-0.02 $-0.02 $-0.03 $-0.03 $-0.02 $-0.05
Operating margin -$257 — — — — — — —

Balance sheet

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Total assets $1.6M $1.5M $1.5M $1.6M $1.6M $1.6M $50.9K $103.8K
Total liabilities $5.7M $5.4M $5.0M $4.5M $4.1M $3.7M $3.4M $3.3M
Stockholders' equity -$4.1M -$3.9M -$3.4M -$2.9M -$2.5M -$2.2M -$3.3M -$3.2M
Total current assets $106.2K $49.5K $49.4K $1.6M $1.6M $1.6M $50.4K $102.5K
Total current liabilities $5.7M $5.4M $5.0M $4.5M $4.1M $3.7M $3.4M $3.3M
Other current assets — — — $1.5M $1.5M $1.5M — —

Cash flow

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Operating cash flow -$248.8K -$374.2K $22.4K -$604.1K $21.6K -$290.2K $414 -$217.9K
Investing cash flow — — — — — — — —
Financing cash flow $249.6K $372.5K -$22.8K $587.2K -$26.6K $321.5K -$32.4K $209.0K
Capital expenditures — — — — — — — —
Share-based compensation $7.3K $15.2K $23.7K $23.7K $23.2K $18.1K $18.8K $18.8K
Change in accounts payable -$122.0K $33.7K -$219.4K $63.3K $10.9K $44.5K $14.4K $45.5K

Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.

Institutional holders

SEC Form 13F filers holding ACUT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

Institutional ownership is not available for this symbol right now.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR Form 4 filings · checked 11 most recent filings · covers 2022-04-25 to 2025-06-13

Recent transactions

  • Most recent: CERRONE GABRIELE M (Director) — Open market purchase of 2,000 shares on 2025-06-13.

Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.

Insider purchases & sales, last 6 months

Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0

Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.

Insider roster

NameTitleMost Recent TransactionDateShares
CERRONE GABRIELE MDirectorOpen market purchase2025-06-132,000

Recent transactions

DateInsiderTitleTransactionSharesPrice
2025-06-13CERRONE GABRIELE MDirectorOpen market purchase 2,000$1.00
2025-06-13CERRONE GABRIELE MDirectorOpen market purchase 400$1.10
2025-06-12CERRONE GABRIELE MDirectorOpen market purchase 8,991$0.83
2025-06-11CERRONE GABRIELE MDirectorOpen market purchase 28,205$0.39
2025-04-09CERRONE GABRIELE MDirectorOpen market purchase 3,000$0.67
2025-04-08CERRONE GABRIELE MDirectorOpen market purchase 35,000$0.67
2025-04-07CERRONE GABRIELE MDirectorOpen market purchase 17,802$0.61
2025-04-07CERRONE GABRIELE MDirectorOpen market purchase 35,000$0.65
2025-03-18CERRONE GABRIELE MDirectorOpen market purchase 100,000$0.45
2024-12-31CERRONE GABRIELE MDirectorOpen market purchase 100,000$0.38

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR submissions · updated 2026-10-22 05:54 UTC

FiledFormReport periodOfficial filing
2026-08-1410-Q2026-06-30 View on SEC.gov →
2026-05-1510-Q2026-03-31 View on SEC.gov →
2026-04-1410-K2025-12-31 View on SEC.gov →
2025-11-268-K2025-11-26 View on SEC.gov →
2025-11-1210-Q2025-09-30 View on SEC.gov →
2025-08-1410-Q2025-06-30 View on SEC.gov →
2025-06-1642025-06-13 View on SEC.gov →
2025-06-1342025-06-11 View on SEC.gov →
2025-05-2010-Q2025-03-31 View on SEC.gov →
2025-04-1042025-04-08 View on SEC.gov →
2025-04-0842025-03-18 View on SEC.gov →
2025-04-0310-K2024-12-31 View on SEC.gov →

Headlines about ACUT (Accustem Sciences Inc). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist